Optison (Perflutren)

Perflutren, the active ingredient in Optison, is a ultrasound contrast agent presented as a suspension for injection for intravenous use. It enhances ultrasound imaging in patients undergoing echocardiography or other diagnostic ultrasound procedures.

GNH USA supplies Optison as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Optison is used as an ultrasound contrast agent to improve visualization in cardiovascular and abdominal imaging procedures. - Echocardiography: improves endocardial border definition for more accurate cardiac function assessment. - Myocardial perfusion imaging: enhances visualization of myocardial blood flow during stress ultrasound studies. - Abdominal ultrasound: provides contrast enhancement that aids detection and characterization of hepatic and renal lesions.

Optison may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, usually resolves spontaneously. - Nausea: occasional, may be alleviated with anti‑emetics if needed. - Injection site pain: brief discomfort at the site of intravenous administration. - Flushing: transient redness and warmth, typically self‑limiting. - Mild hypotension: temporary drop in blood pressure, monitored during the procedure.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or bronchospasm requiring medical attention. - Anaphylaxis: rare but potentially life‑threatening allergic response. - Cardiopulmonary arrest: extremely rare, associated with severe anaphylactic events. - Severe hypotension: marked blood pressure decline needing intervention. - Pulmonary edema: uncommon, may present with dyspnea and crackles.

Prior to administration, clinicians should evaluate patient history and monitor for adverse events. - Assess patient history: check for previous reactions to ultrasound contrast agents. - Monitor vital signs: observe blood pressure, heart rate, and oxygen saturation during and after injection. - Avoid in known hypersensitivity: contraindicated in patients with documented allergy to perflutren or similar agents. - Use with caution in severe cardiac disease: consider hemodynamic stability before injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Optison may interact with other medications or agents that affect cardiovascular or immune responses.

Major Interactions (Avoid): - Concurrent use of other ultrasound contrast agents: increased risk of additive hypersensitivity. - Beta‑blockers: may mask hemodynamic changes during monitoring. - High‑dose vasodilators: potential for exaggerated hypotensive response.

Moderate Interactions (Monitor Closely): - Diuretics: monitor fluid balance and blood pressure. - ACE inhibitors: observe for additive blood pressure effects. - Antihistamines: may alter presentation of allergic reactions, requiring careful observation.